Literature DB >> 32420253

Immunohistochemistry biomarker TP53 expression predicts the survival of thymomas.

Dongliang Bian1, Liting Zhao1, Xuelin Zhang1, Fanzhen Lv1, Zhenghong Zhu1, Hui Qiu2, Huibiao Zhang1.   

Abstract

BACKGROUND: Thymomas are rare malignancies. Thymectomy is the optimal therapy which could prolong the survival of patients. However, prognostic factors of thymomas are not clear.
METHODS: Thymomas patients were enrolled from 2001 to 2016. Clinical and pathological prognostic factors of thymomas were evaluated by univariate and multivariate analyses.
RESULTS: A total number of 98 patients was eligible for this study. All patients were received complete resection (CR). Diagnostic age [elder than the median 60 vs. younger than 60, hazard ratio (HR) =2.325, P=0.027], Masaoka stage (III vs. I, HR =10.756, P<0.001; IV vs. I, HR =6.558, P=0.014), and diabetes mellitus (DM) (with vs. without, HR =0.142, P=0.004) were independent prognostic factors for overall survival (OS). Immunohistochemistry (IHC) biomarker TP53 expression also influenced OS significantly (positive vs. negative, HR =5.157, P=0.018). Furthermore, age (elder than 60 vs. younger than 60, HR =2.980, P=0.022) was independent prognostic factors for recurrence free survival (RFS).
CONCLUSIONS: We found that diagnostic age, clinical stages, DM, TP53 expression in IHC, and quality perioperative nursing are prognostic factors in thymomas. 2020 Gland Surgery. All rights reserved.

Entities:  

Keywords:  TP53; Thymomas; surgery

Year:  2020        PMID: 32420253      PMCID: PMC7225485          DOI: 10.21037/gs.2020.03.01

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  22 in total

1.  Video-Assisted Thoracic Surgery Thymectomy Versus Sternotomy Thymectomy in Patients With Thymoma.

Authors:  Hiroyuki Agatsuma; Kazuo Yoshida; Ichiro Yoshino; Meinoshin Okumura; Masahiko Higashiyama; Kenji Suzuki; Masanori Tsuchida; Jitsuo Usuda; Hiroshi Niwa
Journal:  Ann Thorac Surg       Date:  2017-06-13       Impact factor: 4.330

2.  Does myasthenia gravis influence overall survival and cumulative incidence of recurrence in thymoma patients? A Retrospective clinicopathological multicentre analysis on 797 patients.

Authors:  Pier Luigi Filosso; Andrea Evangelista; Enrico Ruffini; Erino Angelo Rendina; Stefano Margaritora; Pierluigi Novellis; Ottavio Rena; Caterina Casadio; Claudio Andreetti; Francesco Guerrera; Paolo Olivo Lausi; Daniele Diso; Alfredo Mussi; Federico Venuta; Alberto Oliaro; Marco Lucchi
Journal:  Lung Cancer       Date:  2015-03-14       Impact factor: 5.705

3.  Long-Term Survival After Surgical Treatment of Thymic Carcinoma: A Retrospective Analysis from the Chinese Alliance for Research of Thymoma Database.

Authors:  Hao Fu; Zhi-Tao Gu; Wen-Tao Fang; Jian-Hua Fu; Yi Shen; Yong-Tao Han; Zhen-Tao Yu; Yin Li; Li-Jie Tan; Lie-Wen Pang; Ke-Neng Chen
Journal:  Ann Surg Oncol       Date:  2016-02       Impact factor: 5.344

4.  Metformin: Restraining Nucleocytoplasmic Shuttling to Fight Cancer and Aging.

Authors:  Jorge Iván Castillo-Quan; T Keith Blackwell
Journal:  Cell       Date:  2016-12-15       Impact factor: 41.582

Review 5.  The role of chemotherapy in advanced thymoma.

Authors:  Jordan Schmitt; Patrick J Loehrer
Journal:  J Thorac Oncol       Date:  2010-10       Impact factor: 15.609

6.  The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.

Authors:  Matthew W Jackson; David A Palma; D Ross Camidge; Bernard L Jones; Tyler P Robin; David J Sher; Matthew Koshy; Brian D Kavanagh; Laurie E Gaspar; Chad G Rusthoven
Journal:  J Thorac Oncol       Date:  2017-01-25       Impact factor: 15.609

Review 7.  p53 mutations in cancer.

Authors:  Patricia A J Muller; Karen H Vousden
Journal:  Nat Cell Biol       Date:  2013-01       Impact factor: 28.824

8.  Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.

Authors:  Rangaswamy Govindarajan; Luke Ratnasinghe; Debra L Simmons; Eric R Siegel; Madhu V Midathada; Lawrence Kim; Peter J Kim; Randall J Owens; Nicholas P Lang
Journal:  J Clin Oncol       Date:  2007-04-20       Impact factor: 44.544

9.  Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy.

Authors:  Paolo Andrea Zucali; Tommaso De Pas; Giovannella Palmieri; Adolfo Favaretto; Antonio Chella; Marcello Tiseo; Michele Caruso; Matteo Simonelli; Matteo Perrino; Fabio De Vincenzo; Francesca Toffalorio; Vincenzo Damiano; Giulia Pasello; Erika Garbella; Marco Ali; Fabio Conforti; Margaret Ottaviano; Angela Cioffi; Sabino De Placido; Laura Giordano; Monica Bertossi; Annarita Destro; Luca Di Tommaso; Armando Santoro
Journal:  J Clin Oncol       Date:  2017-12-14       Impact factor: 44.544

Review 10.  Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data.

Authors: 
Journal:  Lancet       Date:  2014-02-25       Impact factor: 79.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.